Summarized by Masters of Longevity from Longevity Technology.
ARO‑MAPT lowered CSF tau by about 73% after a subcutaneous dose in healthy adults.
Key Takeaways
- A subcutaneous RNAi drug reduced CSF tau by about 73% in volunteers.
- The treatment was generally well tolerated with mostly mild adverse events.
- Effects on brain tangles and cognition remain unproven in patients.
